A pooled analysis of 13 CVD outcome trials, including more than 83,000 patients reported reductions in MACE (OR 0.86), cardiovascular mortality (OR 0.87), and stroke (fatal OR 0.74, nonfatal OR 0.87) with GLP-1 RA therapy (68). This evidence concerns the gene GLP1R and Stroke.